MYC and cancer: Inhibition of the BET/bromodomain-containing (BRD)4 protein is critical for transcription of the c-Myc promoter and was shown to be effective in an in vivo preclinical mode, implying that targeting c-Myc expression is possible in selected cancers [24,122].